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The peripheral nervous system, in addition to its sensory and motor functions, can induce a local inﬂammatory
response known as neurogenic inﬂammation. This phenomenon plays a critical role in several inﬂammatory
diseases, e.g., asthma, atopy, rheumatoid arthritis, psoriasis, and ulcerative colitis. Neurogenic inﬂammation and
the role of nerve growth factor (NGF) have been extensively studied in psoriasis. There are increased levels of NGF
in the keratinocytes and upregulation of NGF receptor (NGF-R) in the cutaneous nerves of psoriatic plaques. NGF
can inﬂuence all the salient pathologic events noticed in psoriasis such as proliferation of keratinocytes,
angiogenesis, T cell activation, expression of adhesion molecules, proliferation of cutaneous nerves, and
upregulation of neuropeptides. In this double-blinded, placebo-controlled study, we addressed the role of NGF/
NGF-R in psoriasis in an in vivo system using the severe combined immunodeﬁcient (SCID) mouse–human skin
model of psoriasis. The transplanted psoriatic plaques on the SCID mice (n¼ 12) were treated with K252a, a high-
afﬁnity NGF receptor blocker. Psoriasis signiﬁcantly improved following 2 wk of therapy. The length of the rete
pegs changed from 308.57  98.72 to 164.64  46.78 lm (po0.01, Student’s t test). A similar improvement of
psoriasis was observed by directly inhibiting NGF with NGF-neutralizing antibody. NGF-neutralizing antibody in
normal saline at 10 ng (n¼ 4) and 20 ng (n¼ 4) per kilogram of body weight doses were used. Both doses of NGF-
neutralizing antibody reduced rete peg lengths signiﬁcantly, e.g., from 298.5  42.69 to 150.52  32.93 lm (po0.05,
Student’s t test). This study provides evidence for the role of NGF and its high-afﬁnity receptor in the pathogenesis
of psoriasis and insights to develop novel therapeutic modalities.
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A role of neurogenic inflammation in the pathogenesis of
psoriasis is substantiated by a number of observations:
exacerbations during periods of stress, marked proliferation
of terminal cutaneous nerves, and upregulation of neuro-
peptides (SP, VIP, CGRP) in the psoriatic plaques, ther-
apeutic response to neuropeptide-modulating agents such
as capsaicin, somatostatin, and peptide T, and clearance
of active plaques of psoriasis at the sites of anesthesia
following traumatic denervation of cutaneous nerves (Bern-
stein et al, 1986; Farber et al, 1986, 1991; Wallengren et al,
1987; Naukkarinen et al, 1989; Camisa et al, 1990; Leeman
et al, 1991; Raychaudhuri and Farber, 1993; Al’Abadie et al,
1995). The unique features of resolution of psoriasis at sites
of anesthesia, upregulation of neuropeptides and a marked
proliferation of terminal cutaneous nerves in psoriatic
plaques, encouraged us to search for the mechanism of
neural influence. Because nerve growth factor (NGF)
augments tissue innervation (Wyatt et al, 1990) and plays
a critical role in regulating certain neuropeptides such as
SP and CGRP (Schwartz et al, 1982; Lindsay and Harmar,
1989), we investigated the role of NGF in psoriasis. Along
with other investigators we observed that keratinocytes in
lesional and nonlesional psoriatic tissue express high levels
of NGF compared to the controls (Fantini et al, 1995;
Raychaudhuri et al, 1998), and there is a marked upregula-
tion of NGF receptor (NGF-R) in the terminal cutaneous
nerves of psoriatic lesions (Raychaudhuri et al, 2000a, b).
Although clinical and laboratory studies suggest a critical
role of NGF and its receptor (NGF-R) system in the
inflammatory process of psoriasis, it has not yet been
substantiated by any direct evidence. The biologic functions
of the neurotrophins are mediated through two classes of
cell surface receptors, the trk family of tyrosine kinases and
the p75 neurotrophin receptor. NGF, the best-characterized
member of the neurotrophin family, mediates cellular
responses by a high-affinity receptor (trkA) and a low-
affinity receptor (p75). Although the Trk receptors are
responsible for most of the survival and growth properties
of the neurotrophins (Cordon-Cardo et al, 1991; Allsopp
et al, 1993; Majdan et al, 2001), the actions of p75
neurotrophin receptor fall into two categories (Hempstead
et al, 1991; Ross et al, 1996; Maliartchouk and Saragovi,
1997; Majdan et al, 2001). First, p75 neurotrophin receptor
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is a Trk coreceptor that can enhance or suppress
neurotrophin-mediated Trk receptor activity. Second, p75
neurotrophin receptor autonomously activates signaling
cascades that result in the induction of apoptosis or in the
promotion of survival. To determine the significance of NGF/
NGF-R system in the inflammatory process of psoriasis, we
evaluated therapeutic efficacies of K252a, a high-affinity
NGF receptor inhibitor (Koizumi et al, 1988; Lazarovici et al,
1989; Berg et al, 1992), and NGF-neutralizing antibody. In
this study the transplanted psoriatic plaques on the severe
combined immunodeficient (SCID) mouse–human skin
model were treated with intralesional injections of K252a
and NGF-neutralizing antibody.
Results
K252a inhibits nerve regeneration in psoriatic plaques
In each mouse, the acceptance of the human skin graft was
confirmed by histologic and immunohistochemical staining.
Compared to normal skin, increased levels of NGF in the
keratinocytes were maintained in the transplanted psoriatic
plaque (Fig 1a,b).
It is anticipated that marked upregulation of NGF should
augment proliferation of nerves in the transplanted plaques.
Indeed we observed complete regeneration of cutaneous
nerves in the transplanted psoriatic plaques within 4 wk of
transplantation. Nerves stained positively with PGP9.5,
MAP-2, and p75 antibody. We used trkA antibody from
several sources but did not get a good staining of the
nerves. Nevertheless, with the p75 antibody the nerve
staining was best. It showed more nerves in the psoriatic
tissue compared to PGP9.5 and MAP-2. Also p75-stained
nerves were more prominent in respect to the degree of
fluorescence and linear measurement. Because the nerves
stained much better with the p75 antibody and also
upregulation of p75 receptor is a marker of an in vivo effect
of NGF, for quantification of nerve regeneration we used the
data from p75 antibody staining. The numbers of regener-
ated terminal cutaneous nerves positive for NGF-R were
significantly higher in the transplanted psoriatic plaques
compared to the normal human skin grafts as seen in Fig
2(a,c). Grafts took 3 to 4 wk for wound healing; the earliest
biopsies were available on the 4th week of transplantation.
In transplanted normal skin, no nerves could be stained in
the biopsies collected on the 4th week (Fig 2c); few
scattered fine nerves in mid-dermis started appearing in
the 12th week, whereas in transplanted psoriatic plaques in
the 4th week, distinct multiple large nerves traversing from
dermis to the epidermis were identified (Fig 2a). This
suggests the in vivo effect of increased levels of NGF from
the keratinocytes of psoriatic plaques. The same plaque
(Fig 2a) following 2 wk of treatment with K252a does not
demonstrate distinct NGF-R-positive nerves (Fig 2b).
K252a improves clinical, histologic, and immunologic
features of psoriasis Transplanted plaques treated with
K252a had significant clinical and histologic improvement
compared to the controls. After 2 wk of treatment with
K252a, transplanted psoriatic plaques had reduced scales,
erythema, and infiltration. The histologic improvement in the
treated plaques was evidenced by the significant reduction
of hyperkeratosis, acanthosis, and lymphomononuclear
cellular infiltrates (Fig 3a–c; Table I). In Fig 3(a), marked
dermal infiltrates are noticed before treatment, whereas 2
wk after treatment (Fig 3c) with K252a there is barely any
infiltrate in the dermis. In the K252a-treated plaques, there
was significant thinning of the epidermis, the length of the
Figure 1
Histologic section of a transplanted psoriatic plaque demonstrates
marked expression of NGF in the keratinocytes (a) compared to the
normal skin (b). Magnification  400.
Figure 2
Transplanted psoriatic plaque demonstrates marked regeneration of NGF-R-positive nerve fibers. (a). The transplanted psoriatic plaque at the
fourth week of transplantation shows several long-terminal cutaneous nerves positive for NGF-R. (b) The same plaque (a) following 2 wk of treatment
with K252a shows reduced thickness of the epidermis and with only rudimentary NGF-R-positive nerve fibers. Arrows, nerve fiber. Magnification
(a,b)  160. (c) No regeneration of nerves can be seen in the transplanted skin from a normal subject at the fourth week of transplantation.
Magnification  200.
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rete pegs changed from 308.57  98.72 to 164.64  46.78
mm 1 wk after completion of treatment (po0.01, Student’s
t test; Table I). In the control group, the before- and after-
therapy rete peg lengths were 269.37  57.78 and
209.37  74.00 mm (p40.1, Student’s t test) (Table I).
Comparing the K252a arm to the control arm, the changes
in rete peg lengths from before to after therapy were
statistically different from each other (po0.01, Wilcoxon
rank sum test). HLA-DR-positive lymphocytic infiltrates and
intraepidermal CD8þ lymphocytes were significantly
reduced in the K252a-treated plaques. We particularly
focused on these two phenotypes of lymphocytes because
intraepidermal localization of CD8þ lymphocytes is a
unique immunopathologic features of psoriasis and HLA-
DR-positive lymphocytes identifies the activated CD4þ
infiltrates. To demonstrate the infiltrates, we have taken
microphotographs of the histologic sections from before
and after treated transplanted psoriasis plaques. We have
observed that the inflammatory infiltrates (hematoxylin and
eosin staining), HLA-DR-positive lymphocytic infiltrates
and intraepidermal CD8þ lymphocytes were significantly
reduced in the K252a-treated plaques. In pre- and post-
treated tissues intraepidermal CD8þ lymphocytes were
calculated by using a reticule as described earlier (Ray-
chaudhuri et al, 1998, 1999). In the K252a-treated plaques,
the number of CD8þ lymphocytes per square millimeter of
epidermis reduced from 58  10.8 to 12  8.5 1 wk after
completion of treatment (po0.01, Student’s t test). In the
control group, the numbers of CD8þ lymphocytes per
square millimeter of epidermis before and after treatment
were 60  12.8 and 53  15 (p40.1, Student’s t test).
In 12 K252a-treated transplanted plaques, there was a
significant decrease in NGF-R-positive dermal papillary
nerves; the numbers of pre- and post-treatment NGF-R-
positive nerve fiber numbers were 9.8  2.3 and 3.9  1.4
(po0.002, Student’s t test, Table II). In the control group of 8
transplanted plaques the pre- and post-therapy NGF-R-
positive nerve fiber numbers were 7.9  2.1 and 7.9  1.6
(p¼0.97, Student’s t test, Table II). In the untreated group of
4 transplanted plaques, the numbers of NGF-R-positive
nerve fibers were 10  2.6 at 4 wk after transplantation and
10.3  3.9 at 7 wk after transplantation (p¼ 0.95, Student’s t
test). All parameters were examined at synchronized time
points among all groups.
We have taken three serial biopsies at different time
points on several untreated transplanted plaques. We did
not observe any significant exacerbation or improvement of
the histologic features of psoriasis as a result of the trauma
induced by the biopsy procedure. The transplanted psor-
iasis plaques are expected to lose the characteristic
features of psoriasis with time. To address this variation
we kept untreated plaques and plaques treated with saline
as controls. We have observed that immunologic and
histologic features of psoriasis were maintained in the
transplanted plaques for 4 mo. Other investigators have
found similar findings as well (Gilhar et al, 1997; Sugai et al,
Figure 3
Complete resolution of the histologic features of psoriasis following treatment with K252a therapy. (a) Histology of the plaque before
treatment demonstrates the characteristic morphologic features of psoriasis. (b) The lesion 1 wk after completion of intralesional treatment with
K252a demonstrates significant reduction of acanthosis and reduced amount of infiltrates. (c) At the end of 2 wk after treatment complete resolution
of hyperkeratosis, acanthosis and barely any dermal infiltrate can be noticed. Magnification  160.
Table I. Effect of K252a treatment on the rete peg length (lm) of
the transplanted psoriatic plaques (n¼ 20)
Group Before treatment After treatment
K252a treatment:
50 mg BID for
14 days (n¼12)
308.57  98.72 164.64  46.78
Control: normal
saline (n¼ 8)
269.37  57.78 209.37  74.00
814 RAYCHAUDHURI ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
1998; Nickoloff et al, 1995). In this study we completed all
experimental works in each mouse within 8 wk of
transplantation. The control plaques treated with saline for
the same duration did not show any significant improve-
ment, further suggesting that the histologic improvements
were specifically due to therapeutic efficacy of K252a.
To substantiate this observation, we further investigated
whether similar improvement of psoriasis could be induced
by blocking the NGF. Anti-human monoclonal NGF-neutra-
lizing antibody (Wako) was injected intralesionally two times
in a week for 2 wk in eight mice. Doses of NGF-neutralizing
antibody were determined from our earlier in vitro studies
(Raychaudhuri et al, 2001a, b) where we observed that
NGF-neutralizing antibody inhibited NGF-induced T cell
activation, endothelial cell proliferation, and induction of
intercellular adhesion molecule (ICAM-1) on endothelial
cells. In this study, NGF-neutralizing antibody was dissolved
in normal saline and used at the dose of 10 ng (n¼ 4) and
20 ng (n¼4) per kg of body weight. Four control mice were
treated with isotype antibody (IgG2) dissolved in normal
saline. We observed significant improvement of psoriasis in
the NGF-neutralizing antibody-treated transplanted plaques
compared to the plaques treated with placebo (Fig 4a,b).
Rete peg lengths before therapy with 10 and 20 ng per kg of
body weight of NGF antibody were 298.5  42.69 and
306.78  66.96 mm and on the third week following
treatment were 150.52  32.93 and 162.02  38.62 mm,
respectively. In both doses of NGF-neutralizing antibody
reduction of rete peg lengths was statistically significant
(po0.05, Student’s t test), whereas in mice treated with the
placebo, rete peg length before and after treatment were
292.58  68.78 and 310  62.68 mm (Table III).
Discussion
NGF, the best-characterized member of the neurotrophin
family, exerts its effects by binding two classes of
transmembrane receptors, a low-affinity receptor of  75
kDa (p75) (Johnson et al, 1986) and a high-affinity tyrosine
kinase receptor of  140 kDa (TrkA) (Kaplan et al, 1991).
The high-affinity binding site requires expression of the TrkA
proto-oncogene (Bothwell, 1991). TrkA can mediate NGF-
induced effects in the absence of p75 (Klein et al, 1991;
Barbacid, 1993), the functional significance of this low-
affinity receptor in NGF signal transduction is currently
under investigation (Davies, 1997). It has been reported that
p75 can influence the function of trk receptors by
augmenting the affinity of TrkA for NGF (Hempstead et al,
1991). Also it has been shown that p75 forms a complex
with TrkA (Ross et al, 1996) and modulates TrkA trophic
signals (Maliartchouk and Saragovi, 1997).
Both p75 and TrkA are expressed in human keratino-
cytes. Similar to neuronal cells/PC12 cells, in human
keratinocytes NGF also stimulates TrkA phosphorylation.1
Although in human keratinocytes, p75 mRNA and protein
expression are increased during their exponential growth
phase (Di Marco et al, 1993), K252, a potent inhibitor of TrkA
phosphorylation, but not anti-p75, abrogates NGF-induced
keratinocyte proliferation (Pincelli et al, 1994). This suggests
that TrkA is the functional NGF receptor in human
keratinocytes; the role of p75 in respect to effect of NGF
on keratinocyte biology remains to be clarified.
Following injury to the cutaneous nerves, denervated
skin is reinnervated by two mechanisms: axonal regenera-
tion and collateral reinnervation (Devor et al, 1979). NGF has
a regulating role on both of these processes (Taniuchi et al,
Table II. Effect of K252a on NGF-R expression of dermal papillary nerves in the transplanted psoriatic plaques
No. of NGF-R-positive nerve ﬁbers/2-mm punch biopsy (  SD)
Treatment No. of psoriatic plaques Week 0a Week 3 p value
K252a 12 9.8  2.3 3.9  1.4 o0.002
Control (normal saline) 8 7.9  2.1 7.9  1.6 0.97
Untreated 4 10.0  2.6 10.3  3.9 0.95
aWeek 0¼ 4 wk after transplantation.
Figure 4
Histologic improvement of the psoriasis graft treated with NGF-
neutralizing antibody (10 ng per kg of body weight) is evidenced by
thinning of the epidermis and reduction of the infiltrates in the
papillary dermis. (a) Before therapy and (b) after therapy. Magnification
 160.
1Zhai S, Pincelli C, Yaar M, Gonsalves J, Gilchrest BA: The role
of nerve growth factor in preventing keratinocyte apoptosis
[abstract]. J Invest Dermatol 104:572, 1995
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1986; Owen et al, 1989). Further, it has been claimed that
keratinocytes are an important source of NGF for wound
healing, and topical administration of NGF significantly
accelerates regeneration of nerve fibers (Matsuda et al,
1998). An increased level of NGF in keratinocytes of
psoriatic plaques is an established phenomenon (Fantini
et al, 1995; Raychaudhuri et al, 1998). Because mouse and
human NGF are 90% homologous it is likely that mouse
nerves will promptly proliferate into the transplanted
plaques on a SCID mouse. Upregulation of the p75 receptor
is a unique in vivo effect of NGF (Wyatt and Davies, 1993).
Accordingly, we observed a marked proliferation of NGF-R
(p75)-positive nerve fibers in the transplanted psoriatic
plaque compared to the transplanted normal human skin
(Fig 2a,c). These observations substantiate the in vivo effect
of NGF released from the keratinocytes of psoriatic
plaques. Following treatment with K252a we observed that
the number of NGF-R-positive cutaneous nerves in the
treated plaques was markedly reduced (Fig 2b). In K252a-
treated transplanted plaques, there was a significant
decrease in NGF-R-positive dermal papillary nerves, pre-
and post-treatment NGF-R-positive nerve fiber numbers
were 9.8  2.3 and 3.9  1.4 (po0.002, Table II). This
provides further evidence that the lesional NGF in trans-
planted plaques is functionally active.
K252a, an alkaloid toxin isolated from Nocardiopsis, was
originally characterized as an inhibitor of protein kinase C
and cyclic nucleotide-dependent kinases (Kase et al, 1987).
Subsequently, K252a in nanomolar quantities has been
shown to be a specific inhibitor for NGF-induced neuritic
outgrowth in PC12 cell (Koizumi et al, 1988; Lazarovici et al,
1989). The inhibition of cellular effects of NGF by K252a is
mediated by blocking trk proto-oncogene tyrosine phos-
phorylation and kinase activities (Berg et al, 1992). The
functional marker of trk phosphorylation is the activation of
c-fos oncogene transcription (Ehrhard et al, 1993, 1994).
K252a inhibits the trk activity which in turn decreases c-fos
oncogene transcription, increases intracellular calcium, and
stimulates the phosphorylation cascade produced by NGF
in PC12 cells (Lazarovici et al, 1989).
The role of NGF is particularly relevant in the pathogen-
esis of psoriasis. NGF is mitogenic to keratinocytes (Pincelli
et al, 1994; Wilkinson et al, 1994). NGF recruits mast cells
and promotes their degranulation (Aloe and Levi-Mantalcini,
1977; Pearce and Thompson, 1986), both of which are early
events in a developing lesion of psoriasis. In addition, NGF
activates T lymphocytes, recruits inflammatory cellular
infiltrates (Thorpe et al, 1987; Bischoff and Dahinden,
1992; Lambiase et al, 1997), is mitogenic to endothelial
cells, and induces intercellular adhesion molecule on
endothelial cells (Raychaudhuri et al, 2001a, b). NGF is also
known to upregulate the expression of substance p
(Lindsay and Harmar, 1989). Thus, K252a being a potent
inhibitor of the NGF/NGF-R signal transduction system, it is
expected to antagonize these critical events essential for
the inflammatory and proliferative processes of psoriasis.
In this study we observed that treatment with K252a
influenced several salient pathologic features of psoriasis.
Following 2 wk of therapy with K252a, the thickness of the
epidermis/acanthosis reduced from 308.57  98.72 to
164.64  46.78 mm (Table I). In addition downregulation of
HLA-DR expression and marked reduction of dermal CD4þ
and intraepidermal CD8þ T cell infiltrates were noticed.
It is essential to understand the NGF inhibitory functions
of K252a. In the past 15 years, a series of experiments has
been performed by several investigators to demonstrate
that K252a can block NGF-induced neurite outgrowth in
PC12 cells, proliferation of keratinocytes, and activation of
T cells (Koizumi et al, 1988; Lazarovici et al, 1989; Pincelli
et al, 1994). Recently we reported the effects of NGF on
endothelial cell biology. We have observed that NGF is
mitogenic to endothelial cells and induces intercellular
adhesion molecule on endothelial cells (Raychaudhuri et al,
2001a, b). These effects of NGF on endothelial cells are
inhibited by K252a and NGF-neutralizing antibody. Acti-
vated T cells play a significant role in the pathogenesis of
psoriasis. Using SCID–human skin chimeras we have
reported that intralesional injection of autologous peripheral
blood monocytes activated with NGF converts transplanted
nonlesional psoriatic skin to active psoriasis plaques
(Raychaudhuri et al, 2000a, b, 2001a, b). This conversion
does not occur if the autologous peripheral blood mono-
cytes are activated in the presence of a NGF antibody or
K252a.
Keratinocyte proliferation is the most characteristic
histologic feature of psoriasis. NGF by its autocrine action
induces proliferation of keratinocytes; it has been shown
that K252a abrogates NGF-induced keratinocyte prolifera-
tion (Pincelli et al, 1994). It is also reported that autocrine
NGF protects human keratinocytes from apoptosis through
its high-affinity receptor trkA, and keratinocytes treated with
K252a or anti-NGF underwent apoptosis (Pincelli et al,
1997). Increased levels of NGF have been demonstrated in
the keratinocytes of lesional and nonlesional psoriatic skin
(Fantini et al, 1995; Raychaudhuri et al, 1998). Recently, we
carried out a study to investigate whether psoriatic
keratinocytes produce higher amounts of NGF by culturing
keratinocytes from nonlesional psoriatic skin biopsies (data
unpublished). A significant observation was that the
keratinocytes from psoriatic patients synthesized higher
Table III. Effect of NGF-neutralizing antibody therapy on the rete peg length (lm) of the transplanted psoriatic plaques (n¼ 12)
Group Before treatment After treatment
NGF-neutralizing antibody
10 ng/kg, 2  per week for 2 wk (n¼4) 298.50  42.69 150.52  32.93
20 ng/kg, 2  per week for 2 wk (n¼4) 306.78  66.96 162.02  38.62
Control (isotype antibody): 2  per week for 2 wk (n¼4) 292.58  68.78 310.00  62.68
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levels of NGF compared to keratinocytes from normal
subjects. We further noticed that K252a and monoclonal
NGF-R antibody (trk A) inhibited production of NGF and
proliferation of these keratinocytes (Raychaudhuri et al,
2001a, b; S.P. Raychaudhuri, submitted for publication).
Elucidation of the molecular and cellular mechanisms
responsible for the pathogenesis of psoriasis had been
significantly handicapped owing to lack of an ideal animal
model. Recent establishment of the SCID–human skin
chimeras with transplanted psoriasis plaques has opened
new vistas to study the molecular complexities involved in
psoriasis (Nickoloff et al, 1995). Histologic and immunologic
features of psoriasis can be maintained in the transplanted
plaques for more than 3 mo (Gilhar et al, 1997; Sugai et al,
1998) and our experience is that these features are
maintained for more than 6 mo. In this study, we have
demonstrated that K252a, an inhibitor of signal transduc-
tions induced by NGF/NGF-R interaction, is therapeutically
effective in psoriasis. Efficacy is evidenced by decreased
thickness of the rete pegs, reduced infiltrates, and normal-
ization of the stratum corneum, whereas the control group
treated with normal saline did not improve (Table I). A role of
NGF in the pathogenesis of psoriasis is further substan-
tiated by our observation that K252a (a NGF receptor
antagonist) not only improved psoriasis, but a similar
improvement could be reproduced by directly inhibiting
NGF with a NGF-neutralizing antibody. Clinical and histo-
logic improvement of psoriasis observed in this study in
response to NGF-neutralizing antibody and a NGF-R-
blocking agent demonstrates a novel therapeutic approach
for psoriasis.
Materials and Methods
Transplantation of psoriasis plaque on to the SCID mouse
Patients for this study were recruited from the psoriasis clinic of the
Psoriasis Research Institute (Palo Alto, CA). The enrolled patients
had generalized plaque psoriasis, involving 5% to 10% of the total
skin. These patients did not receive any systemic treatment for
psoriasis or phototherapy in the past 6 mo and did not receive any
topical preparations other than emollients in past 6 wk. Shave
biopsies (2.5  2.5 cm) were obtained from active plaques located
on the thigh or arm of 12 psoriatic patients. Each piece of biopsy
was divided into four equal parts of approximately 1 cm2 size.
Thus, 48 grafts on SCID mice were made from 12 shave biopsies
obtained. Twelve grafts were treated with K252a, 8 grafts were
treated with normal physiologic saline, and 4 grafts were kept as
untreated controls. To avoid the individual response variability,
K252a-treated transplanted plaques and the corresponding saline
controls were used from the same patients. The experiments were
conducted after approval by the Institutional Review Board of
Santa Clara Medical Center for human material research. Informed
consent was obtained from each volunteer according to Helsinki
Principles.
The CB17 SCID mice were purchased from The Jackson
Laboratory (Bar Harbor, ME) and housed at the Stanford University
Research Animal Facility (Palo Alto, CA) in a pathogen-free
environment. All experiments were carried out in compliance with
the relevant laws and institutional guidelines. The animal experi-
mental protocol review committee of Stanford University has
approved the protocol for animal experiments. The protocol to use
the plaques of psoriasis was approved by the Medical Review
Board, Santa Clara Valley Medical Center (Santa Clara, CA), and
each donor signed an informed consent. Under general anesthe-
sia, a graft bed of approximately 1 cm2 was created on the shaved
area of the back of a 7- to 8-wk-old mouse by removing a full-
thickness skin sample keeping the vessel plexus intact on the
fascia covering the underlying back muscles. The partial thickness
human skin obtained by shave biopsy was then orthotopically
transferred onto the graft bed. Nexaband liquid, a veterinary
bandage (Veterinary Products Laboratories, Phoenix, AZ), was
used to attach the human skin to the mouse skin, and an antibiotic
ointment (bacitracin) was applied. After 3 tp 4 wk of transplanta-
tion, a 2-mm punch biopsy was obtained to confirm the
acceptance of the graft.
Treatment of the transplanted psoriatic lesions with K252a A
2-mm punch biopsy was obtained before therapy to determine the
psoriatic histology of the graft. Mice of the treatment group
received K252a at 50 mg per kg of body weight BID intralesionally
for 14 days (Alexis Biochemical Corp., San Diego, CA). Each dose
of K252a was dissolved in 150 mL of normal saline. We determined
the dose of K252a on the basis of in vivo and in vitro dose–
response experiments carried out by our group and other
investigators (Raychaudhuri et al, 2001a, b; Pincelli et al, 1994;
Levine et al, 2000). A biologically active and nontoxic dose was
chosen to study its effect on psoriasis. In brief, biologic action was
determined by assessing the dose of K252a for inhibition of NGF-
induced proliferation of keratinocytes, lymphocytes, and endothe-
lial cells. In these experiments, NGF was used at the dose of 25 to
200 ng per mL and K252a was used at the dose of 50 to 200 nM.
We used 100-fold higher doses for in vivo experiments. K252a was
used BID at the dose of 25, 50, and 100 mg in SCID mice to
determine its tolerability. All three doses were well tolerated without
any side effects. We chose the middle dose that is 50 mg BID for
further experiments. Mice of the control group received the same
volume of normal saline. One week after the last (28th) injection,
biopsies were collected from the transplants of both treatment and
control groups. The skin tissues were immediately embedded in
optimal cutting temperature (OCT) reagent and snap-frozen in
liquid nitrogen. Cryosections of 6 to 8 mm were then prepared for
histologic (hematoxylin/eosin) and immunohistochemical staining;
sections of 12 to 14 mm thickness were prepared for cutaneous
nerve staining.
Psoriatic plaques of eight mice were also treated with 10 and
20 ng per kg of body weight of anti-human monoclonal NGF-
neutralizing antibody (Wako, Richmond, VA) with two intralesional
injections per week for 2 wk. Isotype control antibody IgG2 (Wako)
was injected intralesionally twice a week for 2 wk into psoriatic
plaques of four mice. One week after the last injection, biopsies
were collected from the transplants of both NGF-neutralizing
antibody and control groups for histologic examination.
Immunoperoxidase staining for HLA-ABC, HLA-DR, and
NGF The 6- to 8-mm tissue sections were incubated with anti-
HLA-ABC monoclonal antibody (1:1000 dilution) and anti-HLA-DR
antibody (1:100 dilution) (Immunotech, Westbrook, ME) for 18 h
at 41C. For NGF, a polyclonal anti-NGFb antibody (Chemicon
International Inc., Temecula, CA) was used at the dilution of 1:20.
Standard protocol for immunohistochemical staining was followed
(Raychaudhuri et al, 1998, 1999).
Immunoﬂuoresence staining for cutaneous nerves and
CD8 The 12- to 14-mm tissue sections were used to stain the
cutaneous nerves. Sections were incubated with following anti-
bodies: Monoclonal anti-MAP2 antibody (1:200, Sigma, St. Louis,
MO)), anti-NGF-R (p75) monoclonal antibody (1:40 dilution,
Boehringer Mannheim, Germany), and anti-PGP 9.5 monoclonal
antibody (1:800, Ultraclone, Cambridge, UK) for 18 h at 41C. After
being washed, the sections were incubated with fluorescein
isothiocyanate-conjugated horse anti-mouse IgG at 1:100 dilution
(Sigma). For trkA, polyclonal antibodies from two sources
(Chemicon International Inc.; Santa Cruz Biotechnology, Santa
Cruz, CA) were used in various dilutions. CD8 monoclonal antibody
(Boehringer Mannheim, Germany) was used at 1:100 dilution. For
both immunoperoxidase and immunofluorescence staining,
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specificity of the antibodies was confirmed by preabsorbing the
primary antibody and using proper positive and negative controls.
We used a standardized protocol to study terminal cutaneous
nerves in psoriasis plaques (Raychaudhuri et al, 2000a, b). In brief,
nerve regeneration was identified by counting the total number of
NGF-R-positive nerve fibers traversing vertically in the papillary
dermis toward the epidermis in the linear length of the 2-mm
biopsy specimens.
We are grateful to Dr B.J. Nickoloff for his valuable suggestions and
guidance.
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